Introduction {#s1}
============

Chronic inflammatory bowel diseases (IBDs), Crohn\'s disease (CD) and ulcerative colitis (UC), are complex diseases that result from the interaction of numerous genetic and environmental factors [@pone.0098815-Podolsky1].

Genetic association studies have identified innate immunity as a critical component in the development of IBD. Until now, more than 163 IBD susceptibility polymorphisms have been confirmed, most of which are associated with both CD and UC, by candidate and genome wide association studies (GWAS) [@pone.0098815-Jostins1]--[@pone.0098815-Andersen4]. However, these polymorphisms have been estimated to only account for 20% of the genetic heritage involved in IBD [@pone.0098815-Muise1].

Functional polymorphisms in genes in the inflammatory pathways may explain some of the genetic heritage involved in IBD. The transcription factor NFκB is a central regulator of inflammation. NFκB can be activated by Toll like receptors (TLRs). TLRs recognize pathogen-associated molecular patterns (PAMPs) that are broadly shared by pathogens but distinguishable from host molecules such as bacterial or viral DNA, flagellin or lipopolysaccharide (LPS). The TLRs initiates a kinase cascade that ultimately activates the IKK-complex, which phosphorylates and degrades the NFκB inhibitor IκBα. NFκB is shuttled from the cytosol to the nucleus where it initiates expression of pro- and anti-inflammatory cytokines including TNF-α, IL-6 and IL-10 [@pone.0098815-Verstrepen1].

To identify susceptibility loci we assessed 39 mainly functional polymorphisms in genes involved in inflammation, particular in the NFκB pathway, in a homogeneous Danish cohort of 624 patients with severe CD, 411 patients with severe UC and 795 healthy controls. The candidate gene approach using functional polymorphisms allows interpretation of the underlying biological mechanisms based on increased or decreased gene expression or protein activity.

Functional polymorphisms in genes in the inflammatory pathways involved in regulation of the NFκB pathway (*TLR2*, *TLR4*, *TLR5*, *TLR9*, *LY96*, *CD14*, *MAP3K14*, *SUMO4*, *NFKBIA* and *NFKB1*), TNF-α signaling (*TNFA*, *TNFRSF1A* and *TNFAIP3*), cytokines regulated by NFκB (*IL1B*, *IL1RN*, *IL6*, *IL10*, *IL17A* and *IFNG*) and other genes involved in regulation of inflammation (*IL4R*, *IL6R*, *IL23R*, *TGFB1*, *PTPN22*, *PPARG* and *NLRP3*) were studied, as genetically determined variation in the inflammatory pathways may be associated with severe disease among patients with CD and UC.

Materials and Methods {#s2}
=====================

Cohort {#s2a}
------

A prior anti-TNF naïve Danish cohort of patients with IBD was established. In short, blood samples retrieved as part of the routine screening for latent *Mycobacterium tuberculosis* at Statens Serum Institut (SSI, Copenhagen, Denmark) and the Department of Respiratory Diseases B or the Department Clinical Microbiology, Aarhus University Hospital (Aarhus, Denmark) were collected from 01.09.2009 to 30.03.2011 (9217 patients). Patients with intestinal diseases (ICD-10 code K50--K63) were identified by linking the unique personal identification number of Danish citizens (CPR-number) from each blood sample with the National Patient Registry (2659 patients). Patient records from 18 medical departments were examined (1378 patients) and identified 1035 ethnic Danish patients with IBD where blood and clinical data were available. The patients either received or were considered candidates to anti-tumor necrosis factor-α (TNF-α) therapy (infliximab or adalimumab). The control group consisted of 795 healthy blood donors recruited from Viborg, Denmark [@pone.0098815-Ernst1].

Selection of polymorphisms {#s2b}
--------------------------

A candidate gene approach was used with focus on polymorphisms in the TNF-α and NFκB pathways. In addition, polymorphisms in genes which have been shown to be associated with CD and/or UC, polymorphisms in inflammatory cytokines and polymorphisms in *TLR2* and *TLR4* were included [@pone.0098815-Gast1].

Functional polymorphisms in relevant genes were found by searching pubmed with "polymorphism AND gene-name AND (reporter gene OR luciferase OR ELISA OR enzyme-linked immunosorbent assay OR RT-PCR OR reverse transcriptase PCR OR EMSA OR electrophoretic mobility shift assay OR flow cytometry)".

Genotyping {#s2c}
----------

For patients with IBD the DNA was extracted from cryopreserved blood clots by using the Maxwell 16 Blood purification kit (Promega) according to the manufacturers\' instructions with a median yield of 4.90 µg (range 0.8--25 µg) pr 300 µl total blood [@pone.0098815-Bank1]. For the healthy controls, DNA was extracted from EDTA-stabilized peripheral blood by either PureGene (Qiagen, Hilden, Germany) or Wizard Genomic (Promega, Madison, Wisconsin, USA) DNA purification kit according to the manufacturers\' instructions [@pone.0098815-Ernst1]. Competitive Allele-Specific Polymerase chain reaction (KASP), an end-point PCR technology, was used by LGC Genomics for genotyping (LGC Genomics , Hoddesdon, United Kingdom) (<http://www.lgcgenomics.com/>). The SNPs studied were *TLR2* (rs4696480, rs1816702, rs11938228, rs3804099), *TLR4* (rs12377632, rs5030728, rs1554973), *TLR5* (rs5744168), *TLR9* (rs187084, rs352139), *LY96* (MD-2) (rs11465996), *CD14* (rs2569190), *MAP3K14* (NIK) (rs7222094), *SUMO4* (rs237025), *NFKBIA* (IκBα) (rs696, rs17103265), *NFKB1* (NFκB1) (rs28362491), *TNFA* (TNF-α) (rs1800629, rs1800630, rs1799724, rs361525), *TNFRSF1A* (TNFR1) (rs4149570), *TNFAIP3* (A20) (rs6927172), *IL1B* (IL-1β) (rs1143623, rs4848306, rs1143627), *IL-1RN* (IL-1RA) (rs4251961), *IL4R* (rs1805010), *IL6* (rs10499563), *IL6R* (rs4537545), *IL10* (rs1800872, rs3024505), *IL17A* (rs2275913), *IL23R* (rs11209026), *IFNG* (IFN-γ) (rs2430561), *TGFB1* (TGF-β1) (rs1800469), *PTPN22* (rs2476601), *PPARG* (PPAR-γ) (rs1801282) and *NLRP3* (rs4612666).

Genotyping of *TNFA* (TNF-α) −857 C\>T (rs1799724) and −863 C\>A (rs1800630) failed due to their close proximity to each other. All genotyping of −857 C\>T (rs1799724) either failed or were erroneously genotyped as homozygous wild type when the patients were carriers of the AA genotype of −863 C\>A (rs1800630) due to genotyping bias.

The 39 genotypes were replicated in 94 randomly selected samples and yielded \>99% identical genotypes.

Statistical analysis {#s2d}
--------------------

Logistic regression was used to compare genotype distributions among patients with CD, UC and IBD versus healthy controls ([Table S1](#pone.0098815.s001){ref-type="supplementary-material"} and [S2](#pone.0098815.s002){ref-type="supplementary-material"}). Crude odds ratio and odds ratio adjusted for age, gender and smoking status were assessed. A chi-square test was used to test for deviation from Hardy-Weinberg equilibrium in the healthy controls and for haplotype analysis ([Table S3](#pone.0098815.s003){ref-type="supplementary-material"}, [S4](#pone.0098815.s004){ref-type="supplementary-material"}, [S5](#pone.0098815.s005){ref-type="supplementary-material"}).

Statistical analyses were performed using STATA version 11 (STATA Corp., Texas, USA).

Ethics statement {#s2e}
----------------

The study was conducted in accordance with the Declaration of Helsinki and was approved by the Regional Ethics Committees of Central (M20100153) and Southern (S-20120113) Denmark and the Danish Data Protection Agency of Central (RM: J. 2010-41-4719) and Southern (RSD: 2008-58-035) Denmark. The Ethics Committees gave suspension for obtaining written informed consent.

Results {#s3}
=======

Study population {#s3a}
----------------

Characteristics of the Danish patients with CD, UC and healthy controls are shown in [Table 1](#pone-0098815-t001){ref-type="table"}.

10.1371/journal.pone.0098815.t001

###### Description of the study participants.

![](pone.0098815.t001){#pone-0098815-t001-1}

                               Crohns Disease (CD)   Ulcerative Colitis (UC)    Controls
  --------------------------- --------------------- ------------------------- -------------
  **Gender: n (%)**                                                           
  Male                              272 (44)                201 (49)            411 (52)
  Female                            352 (56)                210 (51)            384 (48)
  **Age:**                                                                    
  Median (5%--95%)                 37 (20--67)             42 (20--72)         43 (23--60)
  **Age at diagnosis:**                                                       
  Median (5%--95%)                 25 (14--59)             33 (15--67)             \-
  **Smoking habits: n (%)**                                                   
  Smokers                           178 (29)                 30 (7)             207 (26)
  Former smokers                     64 (10)                 86 (21)            392 (49)
  Never smokers                     156 (25)                102 (25)            189 (24)
  Data not available                226 (36)                193 (47)              7 (1)
  **Location UC: n (%)**                                                      
  Proctitis (E1)                       \-                    53 (13)               \-
  Left side (E2)                       \-                   183 (45)               \-
  Extensive (E3)                       \-                   134 (33)               \-
  Data not available                   \-                    41 (10)               \-
  **Location CD: n (%)**                                                      
  Colonic (L2)                      208 (33)                   \-                  \-
  Ileal (L1)                        172 (28)                   \-                  \-
  Ileocolonic (L3)                  210 (34)                   \-                  \-
  Data not available                 34 (5)                    \-                  \-

The genotype distributions among the healthy controls deviated from Hardy-Weinberg equilibrium for *TLR2* (−16934 A\>T (rs4696480)) (p = 0.02), *TLR4* (rs1554973 T\>C) (p = 0.03), *TLR9* (1174 G\>A (rs352139)) (p = 0.02), and *TGFB1* (−509 C\>T (rs1800469)) (p = 0.02). None of the deviations remained statistically significant after correction for multiple testing.

Polymorphisms associated with risk of CD {#s3b}
----------------------------------------

The homozygous variant genotype of *TLR2* C\>T (rs1816702) (OR~adj~: 2.80, 95% CI: 1.03--7.62, p = 0.04), *TNFRSF1A* −609 G\>T (rs4149570) (OR~adj~: 1.84, 95% CI: 1.19--2.84, p = 0.01) and *IL6R* C\>T (rs4537545) (OR~adj~: 1.73, 95% CI: 1.12--2.66, p = 0.01) were associated with increased risk of CD. Both the homozygous and the heterozygous variant genotypes of *NFKB1* −94ins/del (rs28362491) (OR~unadj~: 0.80, 95% CI: 0.65--1.00, p = 0.05), *IL23R* G\>A (rs11209026) (OR~adj~: 0.38, 95% CI: 0.21--0.67, p = 9\*10^−4^) and *PTPN22* 1858 G\>A (rs2476601) (OR~adj~: 0.57, 95% CI: 0.39--0.83, p = 4\*10^−3^) were associated with reduced risk of CD ([Table S1](#pone.0098815.s001){ref-type="supplementary-material"} and [S2](#pone.0098815.s002){ref-type="supplementary-material"}).

After Bonferroni correction for multiple testing both the homozygous and the heterozygous variant genotypes of *IL23R* G\>A (rs11209026) (OR~adj~: 0.38, 95% CI: 0.21--0.67, p = 0.03) and *PTPN22* 1858 G\>A (rs2476601) (OR~unadj~: 0.54, 95% CI: 0.41--0.72, p = 7\*10^−4^) were associated with reduced risk of CD.

The variant allele of the polymorphisms have been shown to increase TLR2 levels (*TLR2* C\>T (rs1816702)), increase *TNFRSF1A* expression (*TNFRSF1A* −609 G\>T (rs4149570)), increase IL-6r and IL-6 levels (*IL6R* C\>T (rs4537545)), decrease NF-κB p50 subunit expression (*NFKB1* −94ins/del (rs28362491)), decrease IL-17 serum levels (*IL23R* G\>A (rs11209026)) and decrease TNF-α serum levels (*PTPN22* 1858 G\>A (rs2476601)), respectively ([Table 2](#pone-0098815-t002){ref-type="table"}).

10.1371/journal.pone.0098815.t002

###### The biologic effect of the studied single nucleotide polymorphism (SNP) and odds ratios (OR) for polymorphisms which have been shown to be associated with risk of Crohn\'s disease (CD), ulcerative colitis (UC) or inflammatory bowel disease (IBD) in previous studies and in this study.

![](pone.0098815.t002){#pone-0098815-t002-2}

  Gene (SNP)                                                                                                                                                                                             rs-number                                                                                                            Effect of the SNP                                                                                                                                                                                        Previously found associations. Disease, genotype, OR (95% CI), p-value                                                                                                                                                                                                                Associations found in this study. Disease, genotype, OR (95% CI), p-value
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *TLR2* (activates inflammation through the canonical NFκB pathway)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  −16934 A\>T                                                                                                                                                                                            rs4696480                                                                                                      Unknown [@pone.0098815-Gast1]                                                                                                                                                                                                                    ND                                                                                                                                                                                                                                                     IBD: TT, 1.33 (1.01--1.74), p = 0.04[A](#nt101){ref-type="table-fn"}
  C\>A                                                                                                                                                                                                   rs11938228                                                                                                     Unknown [@pone.0098815-Gast1]                                                                                                                                                                                                                    ND                                                                                                                                                                                                                                                                                No association
  C\>T                                                                                                                                                                                                   rs1816702                                                                      rs1816702T increase receptor level[C](#nt103){ref-type="table-fn"} [@pone.0098815-Bielinski1]                                                                                                                                                                                    ND                                                                                                                  CD: TT, 2.36 (1.08--5.16), p = 0.03[A](#nt101){ref-type="table-fn"} ^,^ [B](#nt102){ref-type="table-fn"}; UC: CT or TT, 1.46 (1.10--1.93), p = 0.009[A](#nt101){ref-type="table-fn"} ^,^ [B](#nt102){ref-type="table-fn"}; IBD: CT or TT, 1.32 (1.05--1.65), p = 0.02[A](#nt101){ref-type="table-fn"} ^,^ [B](#nt102){ref-type="table-fn"}
  597 T\>C                                                                                                                                                                                               rs3804099                                                                     597C decrease TNF-α, IL-1β & IL-6 level[E](#nt105){ref-type="table-fn"} [@pone.0098815-Zhang1]                                                                                                                                                                                    ND                                                                                                                                                                                                                                                                                No association
  *TLR4* (activates inflammation through the canonical or non-canonical NFκB pathway)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  G\>A                                                                                                                                                                                                   rs5030728                                                                                                      Unknown [@pone.0098815-Gast1]                                                                                                                                                                                                                    ND                                                                                                                                                                                                                                                                                No association
  T\>C                                                                                                                                                                                                   rs1554973                                                                                                      Unknown [@pone.0098815-Gast1]                                                                                                                                                                                                                    ND                                                                                                                                                                                                               UC: TC or CC, 0.67 (0.48--0.94), p = 0.02[B](#nt102){ref-type="table-fn"}; IBD: CC, 0.67 (0.46--0.98), p = 0.04[A](#nt101){ref-type="table-fn"}
  T\>C                                                                                                                                                                                                   rs12377632                                                                                                     Unknown [@pone.0098815-Gast1]                                                                                                                                                                                                                    ND                                                                                                                                                                                                            UC: TC or CC, 1.42 (1.01--2.00), p = 0.04[B](#nt102){ref-type="table-fn"}; IBD: TC or CC, 1.28 (1.01--1.64), p = 0.05[B](#nt102){ref-type="table-fn"}
  *TLR5* (activates inflammation through the canonical NFκB pathway)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  1174 C\>T                                                                                                                                                                                              rs5744168    1174T (392^STOP^), decrease TNF-α, IL-1β & IL-6 level[G](#nt107){ref-type="table-fn"} [@pone.0098815-Zhang1] and inhibit TLR5 function[D](#nt104){ref-type="table-fn"} ^,^ [E](#nt105){ref-type="table-fn"} [@pone.0098815-Hawn1]                                       CD: CT, 0.14 (0.03--0.57), p = 0.002 (Jewish) [@pone.0098815-Gewirtz1]; CD: No association (Non-Jewish) [@pone.0098815-Gewirtz1], [@pone.0098815-Glas1]                                                                                                                                                                                                      No association
  *TLR9* (activates inflammation through the canonical NFκB pathway)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  −1486 T\>C                                                                                                                                                                                              rs187084                                                                          −1486C&1174G decrease expression[D](#nt104){ref-type="table-fn"} [@pone.0098815-Tao1]                                                                                                                                                                                        ND                                                                                                                                                                                                                                                  IBD: TC or CC, 1.29 (1.00--1.66), p = 0.05[B](#nt102){ref-type="table-fn"}
  1174 G\>A                                                                                                                                                                                               rs352139                                                                          −1486C&1174G decrease expression[D](#nt104){ref-type="table-fn"} [@pone.0098815-Tao1]                                                                                                                                                                                        ND                                                                                                                                                                                                                                                     UC: AA, 0.67 (0.47--0.95), p = 0.03[A](#nt101){ref-type="table-fn"}
  *LY96* (MD-2 binds to and is involved in the TLR2 or the TLR4 complexes)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  −1625 C\>G                                                                                                                                                                                             rs11465996                                                      −1625G increase MD-2 & TNF-α level[D](#nt104){ref-type="table-fn"} ^,^ [E](#nt105){ref-type="table-fn"} [@pone.0098815-Gu1]                                                                                                                                                                     ND                                                                                                                                                                                                                                                     UC: CG, 0.74 (0.57--0.96), p = 0.02[A](#nt101){ref-type="table-fn"}
  *CD14* (binds LPS and transport it to TLR4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  −159 G\>A                                                                                                                                                                                              rs2569190                                                              −159AA increase CD14 level[E](#nt105){ref-type="table-fn"} [@pone.0098815-Baldini1], [@pone.0098815-Mertens1]                                                                                                                                       IBD: GA or AA, 2.95(1.77--4.90),p = 2\*10^−5^ [@pone.0098815-Kim1] (Korean)                                                                                                                                                                                                                                            No association
  *MAP3K14* (NIK is a central kinase in the non-canonical NFκB pathway)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  T\>C                                                                                                                                                                                                   rs7222094                                                                        rs7222094CC decrease NIK activity[E](#nt105){ref-type="table-fn"} [@pone.0098815-Thair1]                                                                                                                                                                                       ND                                                                                                                                                                                                                                                                                No association
  *SUMO4* (SUMO4 conjugates to IκBα and negatively regulates NFκB transcriptional activity)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  163 T\>C                                                                                                                                                                                                rs237025                                                                           163C increase NFκB1 expression[D](#nt104){ref-type="table-fn"} [@pone.0098815-Guo1]                                                                                                                                                                                         ND                                                                                                                                                                                                                                                                                No association
  *NFKBIA* (IkBα is an inhibitor of NFκB1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  2758 G\>A                                                                                                                                                                                                rs696                                                                               2758A increase expression[D](#nt104){ref-type="table-fn"} [@pone.0098815-Song1]                                                                                                                               UC:Extensive colitis (Hungarian) [@pone.0098815-Szamosi1]; CD: Inconclusive [@pone.0098815-Klein1], [@pone.0098815-Hong1]                                                                                                                                                           UC: GA or AA, 1.28 (1.00--1.65), p = 0.05[A](#nt101){ref-type="table-fn"} ^,^ [B](#nt102){ref-type="table-fn"}; CD: No association
  T\>del                                                                                                                                                                                                 rs17103265                                                                        rs17103265del decrease expression[D](#nt104){ref-type="table-fn"} [@pone.0098815-Wang1]                                                                                                                                                                                       ND                                                                                                                                                                                                                                                                                No association
  *NFKB1* (NFκB1 (p50/65) is a transcription factor. The NF-κB p50 subunit can act both pro-inflammatory as part of the p50/p65 complex or anti-inflammatory as p50 homodimer [@pone.0098815-Vogel1])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  −94 ins/del                                                                                                                                                                                            rs28362491                                                   −94del decrease p50 subunit expression[D](#nt104){ref-type="table-fn"} ^,^ [G](#nt107){ref-type="table-fn"} [@pone.0098815-Park1]                                                                                                                                                  Inconclusive [@pone.0098815-Zou1]                                                                                                                                                                                                                                 CD: Ins/- or -/- , 0.80 (0.65--1.00), p = 0.05[A](#nt101){ref-type="table-fn"}
  *TNFA* (TNF-α is a pro-inflammatory cytokine activated by NFκB1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  −863 C\>A                                                                                                                                                                                              rs1800630                                                         −863A increase expression[D](#nt104){ref-type="table-fn"} ^,^ [G](#nt107){ref-type="table-fn"} [@pone.0098815-Udalova1]                                                                                                                                  IBD: AA, 4.82 (2.60--8.96), p = 1\*10^−4^ (Indian) [@pone.0098815-Ahirwar1]                                                                                                                                                                                                                                          Failed to genotype
  −857 C\>T                                                                                                                                                                                              rs1799724                                        −857T increase TNF-α level[D](#nt104){ref-type="table-fn"} ^,^ [E](#nt105){ref-type="table-fn"} ^,^ [F](#nt106){ref-type="table-fn"} [@pone.0098815-Lv1]                                                                                                                                     Inconclusive [@pone.0098815-Ferguson2]                                                                                                                                                                                                                                                            Failed to genotype
  −308 G\>A                                                                                                                                                                                              rs1800629                                                         −308A increase expression[C](#nt103){ref-type="table-fn"} ^,^ [D](#nt104){ref-type="table-fn"} [@pone.0098815-Karimi1]                                                                                                                                                      Inconclusive [@pone.0098815-Ferguson2]                                                                                                                                                                                                                                UC: GA or AA, 0.75 (0.58--0.98), p = 0.04[A](#nt101){ref-type="table-fn"}
  −238 G\>A                                                                                                                                                                                               rs361525                                                         −238A decrease expression[D](#nt104){ref-type="table-fn"} ^,^ [E](#nt105){ref-type="table-fn"} [@pone.0098815-Kaluza1]                                                                                                                                                      Inconclusive [@pone.0098815-Ferguson2]                                                                                                                                                                                                                                                              No association
  *TNFRSF1A* (TNF receptor 1 (TNFR1) binds TNF-α and initiates a kinase cascade)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  −609 G\>T                                                                                                                                                                                              rs4149570                                                                             −609T increase expression[F](#nt106){ref-type="table-fn"} [@pone.0098815-Wang2]                                                                                                                                                                                           ND                                                                                                                     CD: TT, 1.41 (1.02--1.94), p = 0.04[A](#nt101){ref-type="table-fn"} ^,^ [B](#nt102){ref-type="table-fn"}; UC: TT, 1.49 (1.04--2.13), p = 0.03[A](#nt101){ref-type="table-fn"} ^,^ [B](#nt102){ref-type="table-fn"}; IBD: GT or TT, 1.23 (1.02--1.50), p = 0.03[A](#nt101){ref-type="table-fn"} ^,^ [B](#nt102){ref-type="table-fn"}
  *TNFAIP3* (TNF-α rapidly induced expression of *TNFAIP3*/A20 which inhibit NFκB activation and TNF-α mediated apoptosis)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  C\>G                                                                                                                                                                                                   rs6927172                                                       rs6927172G increase expression[D](#nt104){ref-type="table-fn"} ^,^ [G](#nt107){ref-type="table-fn"} [@pone.0098815-Elsby1]                                                                                                                                                                      ND                                                                                                                                                                                                                                                                                No association
  *IL1B* (pro-inflammatory cytokine activated by NFκB1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  −3737 G\>A                                                                                                                                                                                             rs4848306                                                              −3737A decrease transcription[F](#nt106){ref-type="table-fn"} [@pone.0098815-Yoshida1], [@pone.0098815-Chen1]                                                                                                                                                                            ND                                                                                                                                                                                                                                                                                No association
  −1464 G\>C                                                                                                                                                                                             rs1143623                                                               rs1143623C decrease IL-1b level[E](#nt105){ref-type="table-fn"} [@pone.0098815-Chen1], [@pone.0098815-Wen1]                                                                                                                                                                             ND                                                                                                                                                                                                                                                                                No association
  −31 T\>C                                                                                                                                                                                               rs1143627                             −31C decrease expression[D](#nt104){ref-type="table-fn"} ^,^ [E](#nt105){ref-type="table-fn"} ^,^ [G](#nt107){ref-type="table-fn"} [@pone.0098815-Chen1]--[@pone.0098815-Lind1]                                                                                                                   No association (Danish) [@pone.0098815-Andersen1]                                                                                                                                                                                                                                                         No association
  *IL1RN* (IL-1RA binds to the IL-1 receptor and inhibit IL-1β signaling)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  T\>C                                                                                                                                                                                                   rs4251961                                                            rs4251961C decrease IL-1RA level[E](#nt105){ref-type="table-fn"} [@pone.0098815-Rafiq1], [@pone.0098815-Carrol1]                                                                                                                                                                           ND                                                                                                                                                                                                                                                                                No association
  *IL4R* (IL-4 receptor, IL-4 significantly inhibit IL-17 production)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  A\>G (I50V)                                                                                                                                                                                            rs1805010                                                      rs1805010G increase IL-17 level[C](#nt103){ref-type="table-fn"} ^,^ [E](#nt105){ref-type="table-fn"} [@pone.0098815-Wallis1]                                                                                                                                                                     ND                                                                                                                                                                                                                                                                                No association
  *IL6* (pro- and anti-inflammatory cytokine activated by NFκB1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  −6331 T\>C                                                                                                                                                                                             rs10499563                                                        −6331C decrease expression[D](#nt104){ref-type="table-fn"} ^,^ [G](#nt107){ref-type="table-fn"} [@pone.0098815-Smith1]                                                                                                                                                                        ND                                                                                                                                                                                                                                                                                No association
  *IL6R* (binds IL-6 and initiates a kinase cascade)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  C\>T                                                                                                                                                                                                   rs4537545                                                  rs4537545TT increase IL-6r and IL-6 level but not TNF-α, IL-1RA and CRP level[E](#nt105){ref-type="table-fn"} [@pone.0098815-Rafiq2]                                                                                                                                                                 ND                                                                                                                                                                                                                  CD: TT, 1.73 (1.12--2.66), p = 0.01[B](#nt102){ref-type="table-fn"}; IBD: TT, 1.46 (1.02--2.08), p = 0.04[B](#nt102){ref-type="table-fn"}
  *IL10* (activated by NFκB1, capable of inhibiting synthesis of pro-inflammatory cytokines such as IFN-γ and TNF-α)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  −592 C\>A                                                                                                                                                                                              rs1800872                                                                             −592A increase expression[D](#nt104){ref-type="table-fn"} [@pone.0098815-Rees1]                                                                                                                                                                   No association (Danish) [@pone.0098815-Andersen1]                                                                                                                                                                                                                                                         No association
  C\>T                                                                                                                                                                                                   rs3024505                                                                                                    Unknown [@pone.0098815-Andersen1]                                                                                                   CD: T-allele, 1.12 (1.07--1.17),p = 2\*10^−14^ [@pone.0098815-Andersen1], [@pone.0098815-Franke1], [@pone.0098815-Franke2]; UC: T-allele, 1.25 (1.19--1.32), p = 6\*10^−17^ [@pone.0098815-Andersen1], [@pone.0098815-Anderson1]                                                                                   CD: No association; UC: CT or TT, 1.42 (1.10--1.82), p = 0.007[A](#nt101){ref-type="table-fn"}; IBD: CT or TT, 1.25 (1.02--1.52), p = 0.03[A](#nt101){ref-type="table-fn"}
  *IL17A* (activated by NFκB1, pro-inflammatory cytokine, potent mediator in delayed-type reactions, induces the production of IL-1β, IL-6 and TNF-α)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  197G\>A                                                                                                                                                                                                rs2275913                                      197A increase expression[D](#nt104){ref-type="table-fn"} ^,^ [F](#nt106){ref-type="table-fn"} ^,^ [G](#nt107){ref-type="table-fn"} [@pone.0098815-Espinoza1]                                                                                                                                                     ND                                                                                                                                                                                                                                                                                No association
  *IL23R* (IL-23 receptor, IL-23 induce the production of IL-17 and IFN-γ)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  G\>A (R381Q)                                                                                                                                                                                           rs11209026                                                                   rs11209026GG increase IL-17 serum level[E](#nt105){ref-type="table-fn"} [@pone.0098815-Oosting1]                                                                                                          CD: G-allele, 2.66 (2.36--3.00), p = 1\*10^−64^ [@pone.0098815-Franke1]; UC: G-allele, 1.74 (1.57--1.92) , p = 5\*10^−28^ [@pone.0098815-Anderson1]                                                                    CD: GA or AA, 0.39 (0.26--0.59), p = 1\*10^−5A,^ [B](#nt102){ref-type="table-fn"}; UC: GA or AA, 0.59 (0.39--0.90), p = 0.01[A](#nt101){ref-type="table-fn"} ^,^ [B](#nt102){ref-type="table-fn"}; IBD: GA or AA, 0.47 (0.34--0.66), p = 9\*10^−6A,^ [B](#nt102){ref-type="table-fn"}
  *IFNG* (IFN-γ is a pro- and anti-inflammatory cytokine activated by NFκB1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  874 T\>A                                                                                                                                                                                               rs2430561                                                                           874A decrease IFN-γ level[E](#nt105){ref-type="table-fn"} [@pone.0098815-Pravica1]                                                                                                                                                                                          ND                                                                                                                                                                                                                                                                                No association
  *TGFB1* (TGF-β1 is a cytokine which can inhibit the secretion and activity of many other cytokines including IFN-γ and TNF-α)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  −509 C\>T                                                                                                                                                                                              rs1800469                                                          −509T increase expression[D](#nt104){ref-type="table-fn"} ^,^ [G](#nt107){ref-type="table-fn"} [@pone.0098815-Shah1]                                                                                                                                                                         ND                                                                                                                                                                                                                                                                                No association
  *PTPN22* (involved in several signaling pathways associated with the immune response)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  1858 G\>A                                                                                                                                                                                              rs2476601                                                    1858A decrease TNF-α in serum level[E](#nt105){ref-type="table-fn"} ^,^ [F](#nt106){ref-type="table-fn"} [@pone.0098815-Kariuki1]                                                                                                                                CD: G-allele, 1.26 (1.17--1.37), p = 5\*10^−9^ [@pone.0098815-Franke1]                                                                                                                             CD: GA or AA, 0.54 (0.41--0.72), p = 2\*10^−5A,^ [B](#nt102){ref-type="table-fn"}; UC:GA or AA, 0.71 (0.52--0.96), p = 0.03[A](#nt101){ref-type="table-fn"}; IBD: GA or AA, 0.61 (0.48--0.77), p = 4\*10^−5A,^ [B](#nt102){ref-type="table-fn"}
  *PPARG* (PPARγ is a transcription factor)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  C\>G (Pro12Ala)                                                                                                                                                                                        rs1801282                 rs1801282G decrease PPARγ mRNA level, but upregulations MyD88 TLR4, TLR5, TLR9, P65 and TNF-α mRNA levels[E](#nt105){ref-type="table-fn"} ^,^ [F](#nt106){ref-type="table-fn"} [@pone.0098815-Aoyagi1]                              CD:GG, 0.33 (0.12--0.94), p = 0.03 (Hungarian) [@pone.0098815-Poliska1]; CD: No association (Danish) [@pone.0098815-Andersen5]; UC: GG, 2.30 (1.04--5.08), p = 0.04 (Danish) [@pone.0098815-Andersen5]                                                                                                                                         CD: No association; UC: GG, 2.12 (1.01--4.45), p = 0.05[A](#nt101){ref-type="table-fn"}
  *NLRP3* (NALP3 is involved in the inflammasome)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  C\>T                                                                                                                                                                                                   rs4612666                                                                         rs4612666T decrease expression[D](#nt104){ref-type="table-fn"} [@pone.0098815-Hitomi1]                                                                                                                                                                                        ND                                                                                                                                                                                                                                                                                No association

Crude (unadjusted).

Adjusted for age, gender and smoking status.

Function examined by flow cytometry.

Function examined by luciferase reporter assay.

Function examined by enzyme-linked immunosorbent assay (ELISA).

Function examined by reverse transcriptase PCR (RT-PCR).

Function examined by electrophoretic mobility shift assay (EMSA).

ND: not determined.

Thus, polymorphisms associated with higher TLR2 levels (*TLR2* C\>T (rs1816702)), increased *TNFRSF1A* expression (*TNFRSF1A* −609 G\>T (rs4149570)) and higher IL-6r and IL-6 levels (*IL6R* C\>T (rs4537545)) were associated with increased risk of CD. In addition, decreased IL-17 serum levels (*IL23R* G\>A (rs11209026)) and decreased TNF-α serum levels (*PTPN22* 1858 G\>A (rs2476601)) were associated with reduced risk of CD. The NF-κB p50 subunit can act both pro-inflammatory as part of the p50/p65 complex or anti-inflammatory as p50 homodimer ([Table 2](#pone-0098815-t002){ref-type="table"}). A lowered NF-κB p50 subunit expression (*NFKB1* −94ins/del (rs28362491)) could be a differential lowering of the anti-inflammatory response which was associated with reduced risk of CD.

Polymorphisms associated with risk of UC {#s3c}
----------------------------------------

The homozygous variant genotype of *TNFRSF1A* −609 G\>T (rs4149570) (OR~adj~: 1.85, 95% CI: 1.16--2.97, p = 0.01) and *PPARG* C\>G (rs1801282) (OR~unadj~: 2.12, 95% CI: 1.01--4.45, p = 0.05) and both the homozygous and the heterozygous variant genotypes of *TLR2* C\>T (rs1816702) (OR~adj~: 1.63, 95% CI: 1.13--2.36, p = 0.01), *TLR4* T\>C (rs12377632) (OR~adj~: 1.42, 95% CI: 1.01--2.00, p = 0.04), *NFKBIA* 2758 A\>G (rs696) (OR~adj~: 1.45, 95% CI: 1.03--2.05, p = 0.03) and *IL10* C\>T (rs3024505) (OR~unadj~: 1.42, 95% CI: 1.10--1.82, p = 0.01) were associated with increased risk of UC.

The homozygous variant genotype of *TLR9* 1174 G\>A (rs352139) (OR~unadj~: 0.67, 95% CI: 0.47--0.95, p = 0.03) and the heterozygous genotype of *LY96* −1625 C\>G (rs11465996) (OR~unadj~: 0.74, 95% CI: 0.57--0.96, p = 0.02) were associated with reduced risk of UC. In addition, both the homozygous and the heterozygous variant genotypes of *TLR4* T\>C (rs1554973) (OR~adj~: 0.67, 95% CI: 0.48--0.94, p = 0.02), *TNFA* −308 G\>A (rs1800629) (OR~unadj~: 0.75, 95% CI: 0.58--0.98, p = 0.04), *IL23R* G\>A (rs11209026) (OR~adj~: 0.52, 95% CI: 0.29--0.94, p = 0.03) and *PTPN22* 1858 G\>A (rs2476601) (OR~unadj~: 0.71, 95% CI: 0.52--0.96, p = 0.03) were associated with reduced risk of UC ([Table S1](#pone.0098815.s001){ref-type="supplementary-material"} and [S2](#pone.0098815.s002){ref-type="supplementary-material"}). No associations were found after Bonferroni correction for multiple testing.

The variant allele of the polymorphisms have been shown to increase *TNFRSF1A* expression (*TNFRSF1A* −609 G\>T (rs4149570)), increase TLRs and TNF-α mRNA levels (*PPARG* C\>G (rs1801282)), increase TLR2 levels (*TLR2* C\>T (rs1816702)), increase *NFKBIA* expression (*NFKBIA* 2758 A\>G (rs696)), increase MD-2 (*LY96*) and TNF-α levels (*LY96* −1625 C\>G (rs11465996)), increases *TNFA* expression (*TNFA* −308 G\>A (rs1800629)), decrease IL-17 serum levels (*IL23R* G\>A (rs11209026)) and decrease TNF-α serum levels (*PTPN22* 1858 G\>A (rs2476601)), respectively ([Table 2](#pone-0098815-t002){ref-type="table"}). The biological function of the polymorphisms *TLR4* T\>C (rs12377632), *TLR4* T\>C (rs1554973), *TLR9* 1174 G\>A (rs352139) and *IL10* C\>T (rs3024505) are unknown.

Thus, polymorphisms associated with increased *TNFRSF1A* expression (*TNFRSF1A* −609 G\>T (rs4149570)), increased TLRs and TNF-α mRNA levels (*PPARG* C\>G (rs1801282)) and increased TLR2 levels (*TLR2* C\>T (rs1816702)) were associated with increased risk of UC. Furthermore, polymorphisms associated with decreased IL-17 serum levels (*IL23R* G\>A (rs11209026)) and decreased TNF-α serum levels (*PTPN22* 1858 G\>A (rs2476601)) were associated with reduced risk of UC. In contrary, lower activity of the NFκB pathway through increased *NFKBIA* (IκBα) expression (*NFKBIA* 2758 A\>G (rs696)), an inhibitor of the NFκB pathway, was associated with increased risk of UC. In addition, polymorphisms associated with increased MD-2 (*LY96* −1625 C\>G (rs11465996)) and TNF-α levels (*TNFA* −308 G\>A (rs1800629)) were associated with reduced risk of UC.

Polymorphisms associated with risk of IBD {#s3d}
-----------------------------------------

The studied polymorphisms all showed the same direction of effect for both diseases except for the polymorphism in *PPARG* (rs1801282) ([Table S1](#pone.0098815.s001){ref-type="supplementary-material"} and [S2](#pone.0098815.s002){ref-type="supplementary-material"}).

When including all patients (IBD), the homozygous variant genotype of *TLR2* A\>T (rs4696480) (OR~unadj~: 1.33, 95% CI: 1.01--1.74, p = 0.04) and *IL6R* C\>T (rs4537545) (OR~adj~: 1.46, 95% CI: 1.02--2.08, p = 0.04) and both the homozygous and the heterozygous variant genotypes of *TLR2* C\>T (rs1816702) (OR~adj~: 1.42, 95% CI: 1.08--1.88, p = 0.01), *TLR4* T\>C (rs12377632) (OR~adj~: 1.28, 95% CI: 1.01--1.64, p = 0.05), *TLR9* −1486 T\>C (rs187084) (OR~adj~: 1.29, 95% CI: 1.00--1.66, p = 0.05), *TNFRSF1A* −609 G\>T (rs4149570) (OR~adj~: 1.32, 95% CI: 1.03--1.68, p = 0.03) and *IL10* C\>T (rs3024505) (OR~unadj~: 1.25, 95% CI: 1.02--1.52, p = 0.03) were associated with increased risk of IBD. The homozygous variant genotype of *TLR4* T\>C (rs1554973) (OR~unadj~: 0.67, 95% CI: 0.46--0.98, p = 0.04) and both the homozygous and the heterozygous variant genotypes of *IL23R* G\>A (rs11209026) (OR~adj~: 0.43, 95% CI: 0.28--0.67, p = 2\*10^−4^) and *PTPN22* 1858 G\>A (rs2476601) (OR~adj~: 0.62, 95% CI: 0.46--0.85, p = 3\*10^−3^) were associated with reduced risk of IBD ([Table S1](#pone.0098815.s001){ref-type="supplementary-material"} and [S2](#pone.0098815.s002){ref-type="supplementary-material"}).

After Bonferroni correction for multiple testing both the homozygous and the heterozygous variant genotypes of *IL23R* G\>A (rs11209026) (OR~adj~: 0.43, 95% CI: 0.28--0.67, p = 0.007) and *PTPN22* 1858 G\>A (rs2476601) (OR~unadj~: 0.61, 95% CI: 0.48--0.77, p = 0.001) were associated with reduced risk of IBD.

The variant allele of the polymorphisms have been shown to increase IL-6r and IL-6 levels (*IL6R* C\>T (rs4537545)), increase TLR2 levels (*TLR2* C\>T (rs1816702)), increase *TNFRSF1A* expression (*TNFRSF1A* −609 G\>T (rs4149570)), decrease IL-17 serum levels (*IL23R* G\>A (rs11209026)) and decrease TNF-α serum levels (*PTPN22* 1858 G\>A (rs2476601)), respectively ([Table 2](#pone-0098815-t002){ref-type="table"}). The biological function of the polymorphisms *TLR2* A\>T (rs4696480), *TLR4* T\>C (rs12377632), *TLR9* −1486 T\>C (rs187084), *TLR4* T\>C (rs1554973) and *IL10* C\>T (rs3024505) are unknown.

Thus, polymorphisms associated with higher IL-6r and IL-6 levels (*IL6R* C\>T (rs4537545)), higher TLR2 levels (*TLR2* C\>T (rs1816702)) and increased *TNFRSF1A* expression (*TNFRSF1A* −609 G\>T (rs4149570)) were associated with increased risk of IBD. In addition, polymorphisms associated with decreased IL-17 serum levels (*IL23R* G\>A (rs11209026)) and decreased TNF-α serum levels (*PTPN22* 1858 G\>A (rs2476601)) were associated with reduced risk of IBD.

Haplotype analysis {#s3e}
------------------

Haplotype analyses of *TLR2*, *TLR4* and *TLR9* among patients with CD, UC and IBD versus healthy controls are shown in [Table S3](#pone.0098815.s003){ref-type="supplementary-material"}, [S4](#pone.0098815.s004){ref-type="supplementary-material"}, [S5](#pone.0098815.s005){ref-type="supplementary-material"}, respectively. Four haplotypes in *TLR2*, three in *TLR4* and two in *TLR9* described 88%, 94% and 97% of the observed genotypes, respectively.

The *TLR2* haplotype combination 33 encompassing all the wildtype alleles (rs4696480AA, rs11938228CC, rs1816702CC and rs3804099TT) was associated with reduced risk of CD (OR: 0.19, 95% CI: 0.08--0.45, p = 0.00007) and combined CD and UC (OR: 0.32, 95% CI: 0.17--0.60, p = 0.0005).

No associations were found for *TLR4*.

The *TLR9* haplotype combination 11 (rs187084CC and rs352139GG) was associated with increased risk of UC (OR: 1.53, 95% CI: 1.03--2.28, p = 0.04). The *TLR9* haplotype combination 12 was associated with increased risk of IBD (OR: 1.35, 95% CI: 1.04--1.76, p = 0.03). Indirectly, these results support the analysis of the individual SNPs, where the variant allele of rs352139 (included in haplotype combination 22 which was used as reference) was fond to be associated with lowered risk of UC.

Discussion {#s4}
==========

In this study of severely ill patients, 16 functional polymorphisms in 13 genes involved in regulation of inflammation were found to be associated with CD, UC or CD and UC combined (IBD) ([Figure 1](#pone-0098815-g001){ref-type="fig"}). As shown in [Table 2](#pone-0098815-t002){ref-type="table"}, four known susceptibility loci for CD (*PTPN22* (1858 G\>A) [@pone.0098815-Franke1]), UC (*IL10* (rs3024505 C\>T) [@pone.0098815-Andersen1], [@pone.0098815-Anderson1] and *PPARG* (rs1801282 C\>G) [@pone.0098815-Andersen5]) or CD and UC (*IL23R* (rs11209026 G\>A) [@pone.0098815-Franke1], [@pone.0098815-Anderson1]) were replicated. Eleven new polymorphisms associated with risk of CD (*IL6R* (rs4537545 C\>T)), UC (*TLR4* (rs1554973 T\>C and rs12377632 T\>C), *TLR9* (1174 G\>A), *LY96* (−1625 C\>G), *NFKBIA* (2758 A\>G) and *PTPN22* (1858 G\>A)) or CD and UC (*TLR2* (−16934 A\>T and rs1816702 C\>T), *TLR9* (−1486 T\>C) and *TNFRSF1A* (−609 G\>T)) were identified. Other cohort studies of patients with CD and UC have found that other polymorphisms in the *TLR*s (toll like receptors) [@pone.0098815-Cario1] and *TNFRSF*s (TNF receptors) [@pone.0098815-Franke1], [@pone.0098815-Anderson1], [@pone.0098815-Sashio1], [@pone.0098815-Ferguson1] were associated with CD or UC.

![Sixteen functional single nucleotide polymorphisms (SNPs) in 13 genes involved in regulation of inflammation were found to be associated with susceptability of severe Crohn\'s disease (CD), ulcerative colitis (UC) or inflammatory bowel diseases (IBD).\
Eleven of the SNPs have not previously been reported as susceptability polymorphisms of CD, UC or IBD (*TLR2* (rs4696480 and rs1816702), *TLR4* (rs1554973 and rs12377632), *TLR9* (rs187084 and rs352139), *LY96* (rs11465996), *NFKBIA* (rs696), *TNFRSF1A* (rs4149570), *IL6R* (rs4537545) and *PTPN22* (rs2476601)).](pone.0098815.g001){#pone-0098815-g001}

The biological interpretation indicates that a genetically determined higher activity of the inflammatory genes *TLR2* (rs1816702 C\>T), *TNFRSF1A* (−609 G\>T) and *IL6R* (rs4537545 C\>T) was associated with increased risk of CD and lower activity of the inflammatory genes *NFKB1* (NFκB) (−94ins/del ATTG), *IL23R* (rs11209026 G\>A) and *PTPN22* (1858 G\>A) was associated with reduced risk of CD ([Table 2](#pone-0098815-t002){ref-type="table"}). The picture was less clear for UC. A genetically determined higher activity of the inflammatory genes *TNFRSF1A* (−609 G\>T), *PPARG* (rs1801282 C\>G) and *TLR2* (rs1816702 C\>T) was associated with increased risk of UC and lower activity of the inflammatory genes *IL23R* (rs11209026 G\>A) and *PTPN22* (1858 G\>A) was associated with reduced risk of UC. In contrast, a genetically determined higher activity of the NFκB inhibitor IκBα (*NFKBIA* 2758 A\>G) and lower activity of *TLR9* (haplotype 11 (−1486CC and 1174GG)) were associated with increased risk of UC. Furthermore, a genetically determined higher activity of *LY96* (−1625 C\>G) and *TNFA* (−308 G\>A) was associated with reduced risk of UC. However, the risk of CD and UC seem to have shared mechanisms through the *TLR2* (rs1816702 C\>T), *TNFRSF1A* (−609 G\>T), *IL23R* (rs11209026 G\>A) and *PTPN22* (1858 G\>A) polymorphisms confirming that the inflammatory pathways are involved in risk of both CD and UC [@pone.0098815-Franke1], [@pone.0098815-Anderson1].

This study was unable to confirm the associations between the variant allele of *IL10* (rs3024505 C\>T) and increased risk of CD [@pone.0098815-Andersen1], [@pone.0098815-Franke1] or the associations between the variant allele of *CD14* (−159 G\>A) and increased risk of CD, UC and IBD [@pone.0098815-Kim1]. This study may be underpowered to detect an association in *IL10* (rs3024505 C\>T), as a GWA study with more than six thousands CD cases and fifteen thousands control found that the varaint allele was associated with increased risk of CD but with an odds ratio of 1.12 [@pone.0098815-Franke1]. However, *IL10* has previously been found to be associated with risk of CD and UC in the Danish population [@pone.0098815-Andersen1]. The difference of association in *CD14* (−159 G\>A) may be due to genetic differences between the Korean and Danish population.

The variant allele in *NFKBIA* (IκBα) (2758 A\>G) [@pone.0098815-Szamosi1]--[@pone.0098815-Hong1] and *TNFA* (−308 G\>A) were associated with higher and lower risk of UC, respectively, and the deletion polymorphism in *NFKB1* (NFκB) (−94ins/del ATTG) was associated with lower risk of CD in our cohort study. However, there seems to be no consensus regarding these polymorphisms in other cohort studies [@pone.0098815-Klein1]--[@pone.0098815-Ferguson2]. TLR5stop (1174 C\>T) has been found to be associated with reduced risk of CD in a Jewish cohort [@pone.0098815-Gewirtz1] but not in a non-Jewish and German cohort [@pone.0098815-Gewirtz1], [@pone.0098815-Glas1]. No association with TLR5stop was found in this cohort study.

No associations were found for *IL1B* (−31 T\>C) [@pone.0098815-Andersen1], *IL-10* (−592 C\>A) [@pone.0098815-Andersen1] or *PPARG* (rs1801282 C\>G) [@pone.0098815-Andersen5] in accordance with our previous Danish IBD cohort study using independent cases but the same control group [@pone.0098815-Andersen1]. The other polymorphisms studied in *MAP3K14* (rs7222094 T\>C), *SUMO4* (163 T\>C), *TNFAIP3* (rs6927172 C\>G), *IL1RN* (rs4251961 T\>C), *IL4R* (rs1805010 A\>G), *IL6* (−6331 T\>C), *IL17A* (197G\>A), *IFNG* (874 T\>A), *TGFB1* (−509 C\>T) and *NLRP3* (rs4612666 C\>T) were not statistically associated with CD, UC or IBD in our cohort. None of the polymorphisms studied in these genes have been reported to be associated with CD or UC. We can not exclude that we did not find associations between these polymorphisms and risk of disease due to lack of power in this cohort.

The results in this study should be interpreted with care. *TLR2* (rs4696480 A\>T), *TLR4* (rs1554973 T\>C), *TLR9* (1174 G\>A) and *TGFB1* (−509 C\>T) were not in Hardy-Weinberg equilibrium among the healthy controls which is probable due to chance because of the number of polymorphisms analyzed. When corrected adequately for multiple testing they did not deviate from Hardy-Weinberg equilibrium. In the light of the obtained P-values and the number of statistical tests performed, we cannot exclude that some of our positive findings may be due to chance. If the results were corrected for multiple testing only the well known susceptibility polymorphisms in *IL23R* (rs11209026 G\>A) and *PTPN22* (1858 G\>A) were associated with reduced risk of both CD and IBD. We successfully tested 37 polymorphisms and, assuming a 5% acceptance level, two would be expected to be associated with susceptibility by pure chance. In this study 16 polymorphisms were found to be associated with susceptibility and the found associations were biologically plausible. A major strength was that this clinically homogeneous and well-characterised cohort was rather large including 1035 patients with IBD and 795 healthy controls. All the patients were considered for anti-TNF treatment and were therefore considered to have a severe disease course. Genetic determinants may be expected to be strong among severely ill cases [@pone.0098815-Fowler1].

In conclusion, 16 functional SNPs in 13 genes involved in regulation of inflammation were found to be associated with susceptibility of severe CD, UC or IBD. Eleven of the SNPs have not previously been reported as susceptibility polymorphisms of CD, UC or IBD ([Figure 1](#pone-0098815-g001){ref-type="fig"}) although other polymorphisms in most of these genes have previously been associated with susceptibility of CD, UC or IBD. Our results suggest that genetically determined high inflammatory response was associated with increased risk of CD and the large number of polymorphisms in the *TLRs* associated with risk of CD or UC support that the host microbial composition, diet or environmental molecules in the gut are important factors driving the inflammatory response in genetically susceptible individuals.

Supporting Information {#s5}
======================

###### 

**Odds ratios (OR) (unadjusted) for genotypes studied among healthy controls and patients with Crohn\'s disease (CD), ulcerative colitis (UC) and combined inflammatory bowel disease (IBD).**

(DOC)

###### 

Click here for additional data file.

###### 

**Odds ratios (OR) (adjusted for age, sex and smoking status) for genotypes studied among healthy controls and patients with Crohn\'s disease (CD), ulcerative colitis (UC) and combined inflammatory bowel disease (IBD).**

(DOC)

###### 

Click here for additional data file.

###### 

**Association of the** ***TLR2*** **haplotype combinations and risk of Crohn\'s disease (CD), ulcerative colitis (UC) and all inflammatory bowel disease (IBD).**

(DOC)

###### 

Click here for additional data file.

###### 

**Association between** ***TLR4*** **haplotype combinations and risk of Crohn\'s disease (CD), ulcerative colitis (UC) and all inflammatory bowel disease (IBD).**

(DOC)

###### 

Click here for additional data file.

###### 

**Association between** ***TLR9*** **haplotype combinations and risk of Crohn\'s disease (CD), ulcerative colitis (UC) and all inflammatory bowel disease (IBD).**

(DOC)

###### 

Click here for additional data file.

[^1]: **Competing Interests:**PSA, VØT and JS have affiliation to Statens Serum Institut. Statens Serum Institut is not a commercial company. It is a public enterprise under the Danish Ministry of Health (please see <http://www.ssi.dk/English/Service/AboutSSI.aspx>). This does not alter the authors\' adherence to PLOS ONE policies on sharing data and materials.

[^2]: Conceived and designed the experiments: SB PSA MF BAN JS UV VA. Performed the experiments: SB JB NP S. Roug JG SYT JBB S. Rashid BKR SA TBO HJH MKT VØT. Analyzed the data: SB PSA MF BAN JS UV VA. Contributed reagents/materials/analysis tools: SB JB NP S. Roug JG SYT JBB S. Rashid BKR SA TBO HJH MKT VØT MF. Wrote the paper: SB PSA UV VA. Drafting the article or revising it critically: SB PSA JB NP S. Roug JG SYT JBB S. Rashid BKR SA TBO HJH MKT VØT MF BAN JS UV VA. Final approval of the version to be published: SB PSA JB NP S. Roug JG SYT JBB S. Rashid BKR SA TBO HJH MKT VØT MF BAN JS UV VA.
